Orosomucoid in liver diseases

Gulsum Ozlem Elpek

ORCID number: Gulsum Ozlem Elpek 0000-0002-1237-5454.

Author contributions: Elpek GO performed the design of the article, obtained, analyzed and interpreted the data, and wrote the article.

Conflict-of-interest statement: There is not any conflict of interest.

Country/Territory of origin: Turkey

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works

Abstract

In this editorial, the roles of orosomucoid (ORM) in the diagnoses and follow-up assessments of both nonneoplastic diseases and liver tumors are discussed with respect to the publication by Zhu et al presented in the previous issue of World Journal of Gastroenterology (2020; 26(8): 840-817). ORM, or alpha-1 acid glycoprotein (AGP), is an acute-phase protein that constitutes 1% to 3% of plasma proteins in humans and is mainly synthesized in the liver. ORM exists in serum as two variants: ORM1 and ORM2. Although the variants share 89.6% sequence identity and have similar biological properties, ORM1 constitutes the main component of serum ORM. An interesting feature of ORM is that its biological effects differ according to variations in glycosylation patterns. This variable feature makes ORM an attractive target for diagnosing and monitoring many diseases, including those of the liver. Recent findings suggest that a sharp decrease in ORM level is an important marker for HBV-associated acute liver failure (ALF), and ORM1 plays an important role in liver regeneration. In viral hepatitis, increases in both ORM and its fucosylated forms and the correlation of these increases with fibrosis progression suggest that this glycoprotein can be used with other markers as a noninvasive method in the follow-up assessment of diseases. In addition, similar findings regarding the level of the asialylated form of ORM, called asialo-AGP (AsAGP), have been reported in a follow-up assessment of fibrosis in chronic liver disease. An increase in ORM in serum has also been shown to improve hepatocellular carcinoma (HCC) diagnosis performance when combined with other markers. In addition, determination of the ORM level has been useful in the diagnosis of HCC with AFP concentrations less than 500 ng/mL. For monitoring patients with AFP-negative HCC, a unique trifucosylated tetra-antennary glycan of ORM may also be used as a new potential marker. The fact that there are very few studies investigating the expression of this glycoprotein and its variants in liver tissues constitutes a potential limitation, especially in terms of revealing all the effects of ORM on carcinogenesis and tumor behavior. Current findings indicate that ORM2 expression is decreased in tumors, and this is related to the aggressive course of the disease. Parallel to this finding, in HCC cell lines, ORM2 decreases HCC cell migration and invasion, supporting reports of its tumor suppressor role. In conclusion, the levels of ORM and its different glycosylated
Elpek GO. Orosomucoid and liver

variants are promising additional biomarkers for identifying ALF, for monitoring fibrosis in viral hepatitis, and for diagnosing early HCC. Although there is evidence that the loss of ORM2 expression in HCC is associated with poor prognosis, further studies are needed to support these findings. Additionally, investigations of ORM expression in borderline dysplastic nodules and hepatocellular adenomas, which pose diagnostic problems in the differential diagnosis of HCC, especially in biopsy samples, may shed light on whether ORM can be used in histopathological differential diagnosis.

Key Words: Orosomucoid; Alpha-1-acid glycoprotein; Viral hepatitis; cirrhosis; Hepatocellular carcinoma; Downregulation

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

INTRODUCTION

Orosomucoid (ORM), also known as alpha-1 acid glycoprotein (AGP), is an unusual protein with a carbohydrate content of 45% and a very low pI (2.8-3.8) that was identified more than a century ago[1]. Its variation in molecular weight between 37 and 54 kDa is closely related to the differences in its glycosylation content. Although the level of ORM varies according to species, it constitutes 1% to 3% of plasma proteins in humans[2]. This level is slightly higher for men than for women[3]. It is mainly synthesized in the liver; hence, it is also considered a hepatokine. However, smaller amounts can also be produced by breast epithelial cells, type II alveolar epithelial cells, endothelial cells, granulocytes, monocytes, and macrophages[2].

As the name implies, ORM is mainly composed of polypeptide chains and carbohydrate segments. The structures of genes encoding the polypeptide chain of ORM can vary within a broad spectrum. It is located in a cluster of 3 neighboring genes located on the long arm of the 9th chromosome in humans[4]. These neighboring genes are known as AGP-A, AGP-B, and AGP-B'. Among these, AGP-A, which has 3 different alleles (ORM1* S, ORM1* F, and ORM1* F2), encodes ORM-1, and the distribution in the frequency of these alleles in humans may differ according to geographical region[3,5]. AGP-B and AGP-B' encode ORM2. Therefore, ORM exists in human serum as two variants: ORM1 and ORM2[4]. Notably, most individuals carry a mixture of these variants. Although these variants are reported to share 89.6% sequence identity and similar biological properties, ORM1 is the main component of serum ORM, as it is present in plasma at a fivefold higher concentration than ORM2[6,7]. ORM contains 5 N-linked glycans linked to the polypeptide structure, each of which can be a bi-, tri-, or tetra-antennary glycan and can exhibit varying degrees of fucosylation and sialylation and branching[8]. These different glycosylation sites change the protein’s biological properties.

ORM is one of the major acute-phase proteins in humans, and its levels increase 2-fold to 6-fold in plasma in most disease states, including inflammation and cancer. Although the biological role of ORM remains unclear, it can regulate immunity and...
play roles in both pro- and anti-inflammatory responses, can bind to endogenous ligands such as steroids, and has the ability to bind and transport large numbers of basic and neutral lipophilic drugs\[2,8\]. Recent studies have shown evidence that it can affect muscle tissue through glycosylation metabolism, act as an adipokine in adipose tissue, and be involved in bile metabolism\[9-11\]. The general properties of ORM are summarized in Table 1.

Because ORM levels vary in many diseases and since their biological effects depend on the glycosylation pattern, this glycoprotein is an attractive target for use in diagnosis and treatment\[3\]. Accordingly, many current studies are exploring different organs, including the liver, with the aim of using ORM as a potential biomarker for the diagnosis and monitoring of diseases and of revealing its roles in carcinogenesis and tumor behavior.

In this article, the role of ORM in the diagnosis and follow-up of liver diseases is presented.

---

**ORM IN ACUTE LIVER DAMAGE AND REGENERATION**

Loss of liver function caused by viral hepatitis, cirrhosis, alcohol, and drug-induced liver damage is a life-threatening condition. Therefore, many studies have been conducted to better understand liver regeneration mechanisms, mainly to shed light on possible clinical applications, such as in the treatment of acute liver failure (ALF), which is a lethal disease characterized by sudden hepatic metabolic and immunological function loss. Liver regeneration is a complicated but coordinated multistep process that is mediated by the integration of multiple factors. Among these factors, proliferation plays a crucial role in the initiation of regeneration, as suggested by a large amount of data on the activation of the cell cycle and the proliferation of quiescent hepatocytes\[12,13\]. Therefore, eliminating arrest-promoting mechanisms affects the growth of differentiated hepatocytes; in other words, proliferation plays a key role in overcoming liver failure. Although some mitogens, such as growth factors, have been shown to affect proliferation, in recent years, paracrine mediators and nonmitogenic cytokines, including ORM1, have also been shown to participate in the control of this process in a coordinated manner\[14\]. Indeed, ORM1 expression increases during regeneration following liver resection in both humans and mice\[15\].

Moreover, the knockdown of ORM1 downregulates the signaling pathways controlling chromatin replication, supporting the notion that ORM1 plays a role in the cell proliferation involved in liver regeneration\[16\]. This finding is also in line with previous findings related to STAT-3, which is one of the transcription factors involved in liver injury and is associated with proliferation, that show that ORM synthesis is induced in liver injury due to the use of drugs that cause oxidative stress\[17,18\]. In proteomic analyses, it has been suggested that the sharp decrease in serum ORM levels in HBV-induced ALF (HBV-ALF) patients, as indicated by comparisons between liver tissue samples obtained from HBV-ALF and healthy individuals, may be a valuable biomarker in the diagnosis of ALF in patients with chronic liver disease\[19\]. Parallel to these findings, the results from a recent study on HBV-ALF showed the downregulation of four genes involved in the immune response and the complement and coagulation cascades, including ORM1 and ORM2; this suggests that both can be potential treatment targets for ALF\[20\]. However, the tissue expression level of ORM in the liver of patients with HBV-ALF was found to be 4.595-fold higher than that in the liver of healthy patients\[21\]. This finding is partially explained by the hypothesis that blood ORM accumulates in the liver in response to ALF.

Although further studies that involve a large number of patients and analyze both the blood and tissue levels in the same patients are needed to clarify the role of ORM in the diagnosis and treatment of ALF, current evidence indicates that ORM can be a useful marker in the diagnosis of this lethal disease.

---

**ORM AND NONNEOPLASTIC LIVER DISEASES**

As an acute-phase reactant, the ORM level in plasma, which is normally between 4% and 6%, can vary in many inflammatory diseases, including that of the liver. Recently, Oguz et al\[22\] showed that patients with HCV hepatitis have higher ORM levels than healthy individuals. Moreover, evidence has shown that the ORM level fluctuates with fibrosis progression and increases with the development of cirrhosis. Regarding the treatment of HCV hepatitis, no significant difference was found in the responding
Table 1 A brief overview of the general properties of orosomucoid protein

| General properties of orosomucoid protein |
|-----------------------------------------|
| **Chromosome location** | 9 |
| **Genes** | AGP-A, AGP-B and AGP-B' |
| **Product** | ORM1, ORM2 |
| **Alleles** | ORM1, ORM-F, ORM-F2 | Monomorphic, except in Japan |
| **Structure** | | |
| **Polypeptide chain** | Single, 183 amino acids with disulfide bonds; There are 22 amino acid differences between ORM1 and ORM2 |
| **Carbohydrate parts** | Five N-linked potential glycosylation sites: Sialic acid, neutral hexoses, mannose, fructose, galactose and hexosamine. Alterations in fucosylation, sialylation, and branching affect its biological properties |
| **Synthesis** | Predominantly by hepatocytes and parenchymal cells. Extrabiliary secretion is rare (breast, endothelial cells, and tumor cells) |
| **Inflammatory mediators** | Glucocorticoids, TNF-α, Interleukins: 1, 6, 8, 11 |
| **Exogenous factors** | Phenobarbital, Rifampicin, Retinoic acid, Macrolides |
| **Biological activities** | | |
| **Acute-phase reactant** | Concentration is elevated 1-10 times during several pathological conditions. Infection, inflammation, tumor, surgery, tissue injury, sepsis, and septicemia |
| **Immunomodulation** | Inhibit leukocyte rolling/adhesion and migration and lymphocyte proliferation. Vitamin D-mediated macrophage deactivation. Agalacto/asialo derivative suppresses the immune response. ORM1 contributes to both anti- and proinflammatory signals to mediate mechanisms activated by the acute-phase response |
| **Transporting protein** | Drug-binding and transporting in the serum. The existence of two forms in the blood also has an influence on the binding affinity. ORM1 binds warfarin, prazosin, imatinib, quinidine, and dipyridamole. ORM2 binds methadone, disopyramide, propafenone, and amitriptyline |
| **Endothelial functions** | Maintain the barrier function of capillaries. Regulate injury-induced angiogenesis. Enhance blood-brain barrier functional integrity. Beneficial effect on the glomerular barrier |
| **Metabolism** | ORM1 increases glucose uptake activity in adipocytes. A potential biomarker in distinguishing obese women with metabolic syndrome from those without metabolic disturbances |

ORM: Orosomucoid; TNF-α: Tumor necrosis factor alpha.

Elpek GO. Orosomucoid and liver

Group and the nonresponding group, suggesting that ORM levels can only be used as adjuvants to monitor early treatment response. Although not significant, the remarkable increase observed in the early phase of treatment has been attributed to the association of ORM with IFN. In contrast to these findings, another study found that the ORM level in HCV hepatitis was lower than that in healthy subjects and was significantly increased with fibrosis progression[23]. It has been suggested that this decrease may be due to HCV proteins suppressing C3 synthesis. Additionally, variations in the level of ORM were associated with neither necroinflammatory activity nor viral genotype.

High levels of ORM have also been reported in HBV hepatitis and associated cirrhosis[19-21]. In contrast, ORM levels were observed to be within normal limits in NASH and chronic alcoholic liver disease[24,25].

Since the glycosylation pattern of ORM can be modified throughout diseases, these alterations were analyzed for any correlation with the severity of liver diseases to determine the use of ORM as a surrogate marker of fibrosis. In recent years, the fucosylated form of ORM has been observed at a higher level in patients with both HBV and HCV hepatitis than in healthy individuals[26-29]. Moreover, it was emphasized that the fucosylated ORM might be useful in monitoring fibrosis because of its increase with the progression of fibrosis toward cirrhosis[27]. Another interesting finding indicates that during this progression, the increase in ORM fucosylation is associated with a concordant decrease in sialylation. These results support the idea that its glycosylation is modified by the severity of fibrosis and might be useful in disease monitoring[30].

In light of the accumulated data on the modification of the sialylation content of ORM, a few recent studies have been performed to evaluate the diagnostic performance of asialo-AGP (AsAGP) in the detection of cirrhosis in patients with chronic
ORM IN LIVER TUMORS

Hepatocellular carcinoma (HCC) continues to be one of the major causes of cancer deaths worldwide due to its lack of specific clinical findings at the early stages and the lack of efficient screening methods[33]. To prevent HCC from being diagnosed in advanced stages where treatment options are limited, many efforts have been made to identify new diagnostic and screening methods. For this purpose, several tumor markers have been proposed for use in HCC diagnosis. Because evidence has established that ORM is associated with carcinogenesis and behavior in many organs, changes in the ORM serum level in HCC have been investigated as diagnostic markers. The results of many studies have indicated that the ORM level is increased in patients with HCC and is significantly higher than that in patients with chronic hepatitis and cirrhosis[34-37]. ORM has also been shown to improve HCC diagnostic performance when combined with other markers, such as des-g-carboxy prothrombin (DCP)[38].

Furthermore, determination of the ORM level has been observed to be useful in the diagnosis of HCC in which the AFP values are less than 500 ng/mL[39]. In light of these data, it can be concluded that monitoring ORM levels together with AFP and/or other biomarker levels may be useful in the early detection of HCC. Additionally, it has recently been shown that the combination of urinary ORM-I levels with urinary AFP levels has a high sensitivity (85%) in the diagnosis of HCC and that this noninvasive method can also be used[40].

Few studies have evaluated the role of ORM in the evolution and prognosis of cholangiocarcinoma (CCA). An experimental study showed that the ORM2 Level increases before tumor onset and tends to be upregulated during tumor progression[41]. The levels of ORM2 were also investigated in patients with CCA. The sensitivity and specificity of ORM2 in distinguishing CCC patients from healthy individuals were 92.86% and 73.68%, respectively[42].

It has been proposed that alterations in the glycosylation pattern of ORM can be used to detect the progression and metastasis of many types of cancer[43]. Indeed, the aberrant glycosylation of ORM in liver cancer progression has received considerable attention in biomarker studies. Previous studies revealed that although there was an increase in the ORM levels of patients with liver cirrhosis and HCC compared to healthy controls, different degrees of fucosylation may distinguish HCC cases from cirrhosis cases[44-47]. Performing an elegant study, Liang et al[48] demonstrated a unique trifucosylated tetra-antennary glycan of ORM predominantly identified in HCCs. However, this glycan was absent in both healthy subjects and the majority of cirrhosis patients, as determined by matrix-assisted laser desorption ionization-mass spectrometry, providing a new potential marker for monitoring AFP-negative HCC patients. Although the level of fucosylated ORM differs significantly in advanced stages, determining whether these markers can be used to determine HCC behavior requires further studies in large series.

Similar to nonneoplastic diseases of the liver, the efficacy of AsAGP in the diagnosis of HCC has been investigated in some studies. The AsAGP level is higher in cirrhosis and HCC[49,50]. Kim et al[50] revealed that these increases in both cirrhosis and HCC might be related to damaged asialglycoprotein receptors on the hepatic cell surface, as demonstrated in human and animal studies. The release of extra neuraminidase into the circulation during cellular transformation and the production of incomplete asialglycoproteins in hepatic cells are also hypothesized to explain the increase in AsAGP in these patients.

In liver diseases, the vast majority of studies addressing ORM were performed in body fluids. However, there are very few studies that investigated ORM expression at the tissue level that have yielded significant results. Although ORM1 and ORM2 are mostly observed in liver tumors compared to other organ cancers, their expression levels are significantly decreased compared with those in neighboring liver tissue, suggesting that ORM genes are downregulated in liver tumors[37,51,52]. The down-
regulation of ORM2 inversely correlates with intrahepatic metastasis and histological grade; in other words, ORM2 is negatively correlated with aggressive tumor behavior [51]. Parallel to these findings, studies using HCC cell lines showed that ORM2 decreased HCC cell migration and invasion, supporting its tumor suppressor role [32]. In addition, Zhu et al. [52] observed that the prognosis of patients with low ORM2 expression was worse than that of patients with higher ORM2 expression. Therefore, it has been suggested that ORM2 may be a new prognostic factor for liver cancer patients. Moreover, in this study, the inverse association between downregulated ORM2 expression and pathways involved in hepatocarcinogenesis, such as the G2/M checkpoint, E2F target signaling, Wnt/β-catenin, and hedgehog signaling pathways, also supported the use of ORM2 as a marker of liver cancer [51]. The observation of the involvement of ORM2 in tumor-associated macrophage infiltration and the T-cell mediated checkpoint in liver tumor tissue also suggested that its downregulation may be another marker for efficiently predicting the need to apply immune checkpoint therapy. It should be noted that since none of the three current guidelines on the management of HCC include the use of ORM in diagnosis, further studies are needed before recommending its use as a diagnostic marker [53-55]. Moreover, these findings should also be supported by further studies in not only HCC but also CCC. In addition to the relationship of ORM with the immune checkpoint, its relationships with other pathways that may be potential therapeutic targets need to be investigated more comprehensively. The role of ORM expression in differential diagnosis, especially in biopsy samples, to distinguish other neoplastic lesions, such as borderline dysplastic nodules and adenomas, from HCC has not been reported. Furthermore, considering that metastatic tumors of the liver are more common than primary tumors, the role of ORM in these tumors is unknown.

**CONCLUSION**

In addition to being an acute-phase reactant, ORM is a potential biomarker that can be used with other liver markers for the diagnosis of ALF in the follow-up assessment of fibrosis in viral hepatitis. Similarly, it can be used together with other noninvasive methods to detect early stages of HCC. Recent studies suggest that ORM expression may be useful in determining the behavior of HCC and tumor progression. However, in HCC, the relationship of ORM with other pathways targeted for treatment in addition to immune checkpoint pathways should be clarified.

Furthermore, the relationship between metastatic tumors and ORM expression, if any, and its role in the histopathological differential diagnosis of HCC require further investigation.

**REFERENCES**

1. **Tokita K**, Schmid K. Variants of alpha-1-acid glycoprotein. *Nature* 1963; **200**: 266 [PMID: 14081071 DOI: 10.1038/200266a0]
2. **Luo Z**, Lei H, Sun Y, Liu X, Su DF. Orosomucoid, an acute response protein with multiple modulating activities. *J Physiol Biochem* 2015; **71**: 329-340 [PMID: 25711902 DOI: 10.1007/s13105-015-0389-9]
3. **Keser T**, Tijardović M, Gornik I, Lukić E, Lauc G, Gornik O, Novokmet M. High-throughput and site-specific N-glycosylation analysis of human alpha-1-acid glycoprotein offers a great potential for new biomarker discovery. *Mot Cell Proteomics* 2021; **100044** [PMID: 33493676 DOI: 10.1074/mcp.RA120.002433]
4. **Smith SA**, Waters NJ. Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein. *Pharm Res* 2018; **36**: 30 [PMID: 30593605 DOI: 10.1007/s11095-018-2551-x]
5. **Utetsu K**, Yuasa I, Harada A, Suzuki T, Pan IH, Ishida T, Saitou N, Horai S. Orosomucoid phenotyping with monoclonal antibodies polymorphic occurrence of ORM1*Q6* in aboriginal Taiwanese populations. *Hum Hered* 1995; **45**: 181-185 [PMID: 7558048 DOI: 10.1159/000154286]
6. **Carter KC**, Post DJ, Papaconstantinou J. Differential expression of the mouse alpha-1-acid glycoprotein genes (AGP-1 and AGP-2) during inflammation and aging. *Biochim Biophys Acta* 1991; **1089**: 197-205 [PMID: 2054382 DOI: 10.1016/1674-7809(91)90008-a]
7. **Ye X**, Zhang N, Jin Y, Xu B, Guo C, Wang X, Su Y, Yang Q, Song J, Yu W, Cheng P, Cheng L, Gong Y, Fu X, Sun H. Dramatically changed immune-related molecules as early diagnostic biomarkers of non-small cell lung cancer. *FEBS J* 2020; **287**: 783-799 [PMID: 31482685 DOI: 10.1111/febs.15051]
8. **Ceciliani F**, Lecchi C. The Immune Functions of α, Acid Glycoprotein. *Curr Protein Pept Sci* 2019;
20. Sun Y, Qin Z, Wan J, Wang PY, Yang YL, Yu JG, Hu BH, Su DF, Luo ZM, Liu X. Estrogen weakens muscle endurance via estrogen receptor-p38 MAPK-mediated orosomucoid (ORM) suppression. Exp Mol Med 2018; 50: e463 [PMID: 29896924 DOI: 10.1038/emm.2017.307]

21. Cheng S, Wiklund P, Autio R, Borra R, Ojanen X, Xu L, Törnökangas T, Alen M. Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. JLoS One 2015; 10: e0138889 [PMID: 26439744 DOI: 10.1371/journal.pone.0138889]

22. Porez G, Gross B, Prawitt J, Gheeraert C, Berrahal W, Alexandre J, Stael P, Lebèvre P. The hepatic orosomucoid/α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR. Endocrinology 2013; 154: 3690-3701 [PMID: 23861371 DOI: 10.1210/en.2013-1263]

23. Schaub JR, Malato Y, Gormond C, Willenbring H. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. Cell Rep 2014; 8: 933-939 [PMID: 25131204 DOI: 10.1016/j.celrep.2014.07.003]

24. Yanger K, Stanger BZ. Liver cell reprogramming: parallels with iPSC biology. Cell Cycle 2014; 13: 1211-1212 [PMID: 24621496 DOI: 10.4161/cc.28381]

25. Kiseleva YV, Antontyan SZ, Zharkovs TS, Tuptikin KA, Kalinin DV, Zharikov YO. Molecular pathways of liver regeneration: A comprehensive review. World J Hepatol 2013; 11: 270-290 [PMID: 33815672 DOI: 10.4254/wjh.v13.3.270]

26. Qin XY, Mara H, Arner E, Kawaguchi Y, Inoue I, Tatsuaka H, Furutani Y, Nagatsuma K, Matsuura T, Wei F, Kikuchi J, Sone H, Daub C, Kawai H, Lassmann T, Itoh M, Suzuki H, Carninci P, Hayashizaki Y; FANTOM consortium, Kokudo N, Forrest ARR, Kojima S. Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes. EBioMedicine 2017; 24: 257-266 [PMID: 28977749 DOI: 10.1016/j.ebiom.2017.09.008]

27. Min JS, DeAngelis RA, Reis ES, Gupta S, Mauya MR, Evans C, Das A, Burant C, Lambris JD, Subramaniam S. Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration. J Immunol 2016; 197: 2500-2508 [PMID: 27157733 DOI: 10.4049/jimmunol.1600628]

28. Tacchini L, Fusar-Poli D, Bemmel-Zazzera A. Activation of transcription factors by drugs inducing oxidative stress in rat liver. Biochem Pharmacol 2002; 63: 139-148 [PMID: 11841787 DOI: 10.1016/s0006-2952(01)00836-x]

29. Tacchini L, Fusar-Poli D, Sironi M, Mantovani A, Bemmel-Zazzera A. Activation of signal transducer and activator of transcription 3 in rat liver after heat shock and reperfusion stress. Int J Biochem Cell Biol 2003; 35: 316-323 [PMID: 12531244 DOI: 10.1016/j.hcc.2003-07-30521-8]

30. Ren F, Chen Y, Wang Y, Yan Y, Zhao J, Ding M, Zhang J, Jiang Y, Zhai Y, Duan Z. Comparative serum proteomic analysis of patients with acute-on-chronic liver failure: α1-acid glycoprotein maybe a candidate marker for prognosis of hepatitis B virus infection. J Viral Hepat 2010; 17: 816-824 [PMID: 20002297 DOI: 10.1111/j.1365-2893.2009.01242.x]

31. Lin H, Zhang Q, Li X, Wu Y, Liu Y, Hu Y. Identification of key candidate genes and pathways in hepatitis B virus-associated acute liver failure by bioinformatical analysis. Medicine (Baltimore) 2018; 97: e9687 [PMID: 29384847 DOI: 10.1097/MD.0000000000009867]

32. Peng L, Liu J, Li YM, Huang ZL, Wang PP, Zheng YB, Hua YP, Gao ZL. iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure. Exp Ther Med 2015; 10: 1732-1742 [PMID: 26640544 DOI: 10.3892/etm.2015.2727]

33. Ogur A, Atay AE, Tas A, Seven G, Koruk M. Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection. Gut Liver 2013; 7: 82-88 [PMID: 23424009 DOI: 10.5009/gnl.2013.7.1.82]

34. Atta M, Cabral M, Santos G, Paraná R, Atta A. Inflammation biomarkers in chronic hepatitis C: association with liver histopathology, HCV genotype and cryoglobulinemia. Inflamm Res 2012; 61: 1101-1106 [PMID: 22718074 DOI: 10.1007/s00011-012-0502-2]

35. Koruk M, Tayı S, Savaş MC, Yılmaz AO, Akçay F, Karakoç M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2013; 14: 353-357

36. Tsutsuimi M, Takase S. Usefulness of microheterogeneity of serum alpha 1-acidglycoprotein as a marker for alcohol abuse. Alcohol 2001; 25: 181-184 [PMID: 11389463 DOI: 10.1016/s0741-8329(01)00181-1]

37. Mondal G, Chattjeepee U, Das HR, Chattjeepee BP. Enhanced expression of alpha1-acid glycoprotein and fucosylation in hepatitis B patients provides an insight into pathogenesis. Glycoconj J 2009; 26: 1225-1234 [PMID: 19459043 DOI: 10.1007/s10719-009-9241-1]

38. Mooney P, Hayes P, Smith K. The putative use of alpha1-acid glycoprotein as a non-invasive marker of fibrosis. Biomed Chromatogr 2006; 20: 1351-1358 [PMID: 17094233 DOI: 10.1002/bmc.704]

39. Anderson N, Pollacciuh A, Hayes P, Theraponides G, Newsome P, Boyter A, Smith K. A preliminary evaluation of the differences in the glycosylation of alpha1-acid glycoprotein between individual liver diseases. Biomed Chromatogr 2002; 16: 365-372 [PMID: 12228891 DOI: 10.1002/bmc.167]

40. Rydén I, Pålsson P, Lindgren S. Diagnostic accuracy of alpha(1)-acid glycoprotein fucosylation for liver cirrhosis in patients undergoing hepatic biopsy. Clin Chem 2002; 48: 2195-2201 [PMID: 12446476]

41. Mandal G, Yagi H, Kato K, Chatterjee BP. Structural heterogeneity of glycoform of alpha-1 Acid glycoprotein in alcoholic cirrhosis patients. Adv Exp Med Biol 2015; 842: 389-401 [PMID: 25408356 DOI: 10.1007/978-3-319-11280-0_24]
Elpek GO. Orosomucoid and liver

31 Lim DH, Kim M, Jun DW, Kwak MJ, Yoon JH, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS, Kang BK. Diagnostic Performance of Serum Asialo α1-Acid Glycoprotein Levels to Predict Liver Cirrhosis. Gut Liver 2021; 15: 109-116 [PMID: 32066208 DOI: 10.5009/gnl19282]

32 Kim SU, Jeon MY, Lim TS. Diagnostic Performance of Serum Asialo-α1-Acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2019; 74: 341-348 [PMID: 31870140 DOI: 10.4146/kg.2019.74.6.341]

33 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

34 Omran MM, Enman TM, Farid K, Eltaweel FM, Omar MA, Bazeed FB. An Easy and Useful Noninvasive Score Based on α-1-Acid Glycoprotein and C-Reactive Protein for Diagnosis of Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection. J Immunassay Immunochromatogr 2016; 37: 273-288 [PMID: 26685049 DOI: 10.1080/15321815.2015.1132220]

35 Gani RA, Suryamin M, Hasan I, Lesmana CR, Sanitoyo SA. Performance of Alpha Fetoprotein in Combination with Alpha-1-Acid Glycoprotein for Diagnosis of Hepatocellular Carcinoma Among Liver Cirrhosis Patients. Acta Med Indones 2015; 47: 216-222 [PMID: 26586387]

36 Bachtiari I, Santosoo JM, Atmanegara B, Gani RA, Hasan I, Lesmana LA, Sulaiman A, Gu J, Tai S. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin Chim Acta 2009; 399: 97-101 [PMID: 18926809 DOI: 10.1016/j.cca.2008.09.024]

37 Cao QW, Jiang BY, Huang JM, Zhang L, Liu MQ, Yao J, Wu MX, Zhang LJ, Kong SY, Wang Y, Yang PY. Straightforward and Highly Efficient Strategy for Heterocellular Carcinoma Glycoprotein Biomarker Discovery Using a Nonglycopeptide-Based Mass Spectrometry Pipeline. Anal Chem 2019; 91: 12435-12443 [PMID: 31453685 DOI: 10.1021/acs.analchem.9b03074]

38 Bachtiari I, Kheng V, Wibowo GA, Gani RA, Hasan I, Sanitoyo SA, Budhihusodo U, Lelosutan SA, Martamala R, Achwan WA, Soemoharjo S, Sulaiman A, Lesmana LA, Tai S. Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma. BMC Res Notes 2010; 3: 319 [PMID: 21092242 DOI: 10.1186/1756-0500-3-319]

39 Kang X, Sun L, Guo K, Shu H, Yao J, Qin X, Liu Y. Serum biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS. J Cancer Res Clin Oncol 2010; 136: 1151-1159 [PMID: 20309913 DOI: 10.1007/s00216-010-0762-6]

40 Zhan Z, Guan Y, Mew K, Zeng W, Peng M, Hu P, Yang Y, Lu Y, Ren H. Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 2020; 318: G305-G312 [PMID: 31736338 DOI: 10.1152/ajpgi.00267.2019]

41 Rucksaken R, Khootawad J, Joytrakul S, Pinlaor P, Hiraku Y, Wongkham C, Paipoju K, Boonmuang T, Pinlaor S. Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer Biomark 2012; 12: 81-95 [PMID: 23396253 DOI: 10.3233/CBM-130296]

42 Rucksaken R, Charoenusuk L, Pinlaor P, Paipoju K, Khuventico N, Pinlaor S. Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma. Cancer Biomark 2017; 18: 27-34 [PMID: 27814272 DOI: 10.3233/CBM-160670]

43 Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, Poland RC, van Dijk W, Kuvano H, Kuchibe N, Yazawa S. α1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004; 101: 2825-2836 [PMID: 15536618 DOI: 10.1002/cncr.20713]

44 Zhang D, Huang J, Luo D, Feng X, Liu Y. Glycosylation change of α1-acid glycoprotein as a serum biomarker for hepatocellular carcinoma and cirrhosis. Biomark Med 2017; 11: 423-430 [PMID: 28621608 DOI: 10.2217/bmm-2016-0284]

45 Åström E, Stål P, Zenlander R, Edvink P, Alexandersson C, Haglund M, Rydén I, Pålsson P. Reverse lectin ELISA for detecting fucosylated forms of α1-acid glycoprotein associated with hepatocellular carcinoma. PLoS One 2017; 12: e0173897 [PMID: 28296934 DOI: 10.1371/journal.pone.0173897]

46 Ji ES, Huang H, Park GW, Lee JY, Lee HK, Choi NY, Jeong HK, Kim KH, Kim JY, Lee S, Ahn YH, Yoo JS. Analysis of fucosylation in liver-secreted N-glycoproteins from human hepatocellular carcinoma plasma using liquid chromatography with tandem mass spectrometry. Anal Bioanal Chem 2016; 408: 7761-7774 [PMID: 27565792 DOI: 10.1002/abjc.2016-016-0987-0]

47 Tanabe K, Kitagawa K, Kojima N, Iijima S. Multifucosylated α1-acid Glycoproteins as a Novel Marker for Hepatocellular Carcinoma. J Proteome Res 2016; 15: 2935-2944 [PMID: 27354006 DOI: 10.1021/acs.jproteome.5b01145]

48 Liang J, Zhu J, Wang M, Singal AG, Odewole M, Kagan S, Renteria V, Liu S, Parikh ND, Lubman DM. Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. Sci Rep 2019; 9: 11580 [PMID: 31399619 DOI: 10.1038/s41598-019-48043-1]

49 Song EY, Kim KA, Kim YD, Lee EY, Lee HS, Kim HJ, Ahn BM, Choe YK, Kim CH, Chung TW. Evaluation of serum asialo-alpha(1) acid glycoprotein concentration in patients with hepatic cirrhosis and hepatocellular carcinoma as measured by antibody-lectin sandwich assay. Hepatol Res 2003; 26: 311-317 [PMID: 12963431 DOI: 10.1046/s1386-6346(03)00156-6]

50 Kim KA, Lee EY, Kang JH, Lee HG, Kim JW, Kwon DH, Kang YJ, Yeom YI, Chung TW, Kim YD,
Yoon DY, Song EY. Diagnostic accuracy of serum asialo-alpha1-acid glycoprotein concentration for the differential diagnosis of liver cirrhosis and hepatocellular carcinoma. *Clin Chim Acta* 2006; 369: 46-51 [PMID: 16472796 DOI: 10.1016/j.cca.2006.01.002]

51 Fang T, Cui M, Sun J, Ge C, Zhao F, Zhang L, Tian H, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li H, Li J. Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas. *Oncotarget* 2015; 6: 16106-16119 [PMID: 25965830 DOI: 10.18632/oncotarget.3867]

52 Zhu HZ, Zhou WJ, Wan YF, Ge K, Lu J, Jia CK. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. *World J Gastroenterol* 2020; 26: 804-817 [PMID: 32148378 DOI: 10.3748/wjg.v26.i8.804]

53 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; 11: 317-370 [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9]

54 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* 2019; 70: 172-193 [PMID: 30144956 DOI: 10.1016/j.jhep.2018.06.024]

55 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; 68: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]
